EXTH-52. EGFRvIII: A NEW PREDICTIVE BIOMARKER FOR TEMOZOLOMIDE RESPONSE IN MGMT PROMOTOR METHYLATED GLIOBLASTOMA PATIENTS

Despite many clinical efforts, the prognosis of GBM patients has not improved in the last 10 years. Epigenetic silencing of the O6-methylguanine-DNA-methyltransferase (MGMT) gene is the only predictive biomarker that is associated with temozolomide (TMZ) response. The establishment of new biomarkers...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Neuro Oncol
Hlavní autoři: Struve, Nina, Brend, Tim, Stead, Lucy, Binder, Zev A, Ott, Leonie, Muller-Goebel, Justus, Hoffer, Konstatin, Morrissette, Jennifer J D, Petersen, Cordula, Rothkamm, Kai, O’Rourke, Donald, Short, Susan C, Kriegs, Malte
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2017
Témata:
Abstracts
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5692225/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.344
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky